NCT00515034View on ClinicalTrials.gov

A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Pneumonia, Ventilator-AssociatedPneumonia, BacterialPneumoniaAbdominal AbscessBacterial Infections
Interventions
DRUG

Imipenem/cilastatin

Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion

DRUG

Imipenem/cilastatin

Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion

DRUG

Doripenem

1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days

DRUG

Doripenem

1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00515034 - A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia | Biotech Hunter | Biotech Hunter